https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct03674567-2026-09-03 Hipa.ai en 2026-09-03T00:00:00.000Z Pembrolizumab Trial Results Posted in Advanced Cancer Study https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct04246177-2026-09-03 Hipa.ai en 2026-09-03T00:00:00.000Z Pembrolizumab trial shows longer PFS, no OS gain in HCC https://hipa.ai/drug/rimegepant/updates/trial-results-posted-nct05810038-2026-09-03 Hipa.ai en 2026-09-03T00:00:00.000Z Rimegepant reduces migraine days in Phase 3 Chinese trial https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct03179917-2026-09-02 Hipa.ai en 2026-09-02T00:00:00.000Z Pembrolizumab trial reports Hodgkin lymphoma response counts https://hipa.ai/drug/atezolizumab/updates/trial-results-posted-nct03502785-2026-09-02 Hipa.ai en 2026-09-02T00:00:00.000Z Atezolizumab Trial Reports 40% ORR in Untreated Cohort https://hipa.ai/drug/canagliflozin/updates/trial-results-posted-nct05237960-2026-09-02 Hipa.ai en 2026-09-02T00:00:00.000Z Canagliflozin: Metformin Oral Cancer Trial Results Posted https://hipa.ai/drug/canagliflozin/updates/boxed-warning-present-label-metformin-hydrochloride-label-2026-09-01 Hipa.ai en 2026-09-01T00:00:00.000Z Canagliflozin Label Lists Boxed Warning for Metformin Acidosis https://hipa.ai/drug/tofacitinib/updates/boxed-warning-revised-tofacitinib-label-effective-2026-09-01-2026-09-01 Hipa.ai en 2026-09-01T00:00:00.000Z Tofacitinib boxed warning revised effective September 1, 2026 https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct04209686-2026-09-01 Hipa.ai en 2026-09-01T00:00:00.000Z Pembrolizumab trial reports survival in advanced gastric cancer https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct05508867-2026-09-01 Hipa.ai en 2026-09-01T00:00:00.000Z Pembrolizumab Trial in Hodgkin Lymphoma Shows Mixed Results https://hipa.ai/drug/pembrolizumab/updates/phase-3-primary-completion-nct06687369-2026-08-31 Hipa.ai en 2026-08-31T00:00:00.000Z Pembrolizumab Biosimilar Phase 3 Trial Reaches Primary Completion https://hipa.ai/drug/pembrolizumab/updates/phase-3-primary-completion-nct02954874-2026-08-31 Hipa.ai en 2026-08-31T00:00:00.000Z Pembrolizumab trial reaches primary completion in TNBC https://hipa.ai/drug/nivolumab/updates/trial-results-posted-nct03743766-2026-08-31 Hipa.ai en 2026-08-31T00:00:00.000Z Nivolumab Trial Reports Melanoma Biomarker Measurements https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct05756166-2026-08-31 Hipa.ai en 2026-08-31T00:00:00.000Z Pembrolizumab trial in metastatic TNBC reports no responses https://hipa.ai/drug/itepekimab/updates/trial-results-posted-nct05326412-2026-08-31 Hipa.ai en 2026-08-31T00:00:00.000Z Itepekimab trial reports airway inflammation biomarker changes